Allergan acquires AqueSys, adds Xen45 to pipeline

Allergan has completed the acquisition of AqueSys in an all-cash transaction, according to a press release. The acquisition includes a $300 million up-front payment and potential regulatory approval and commercialization milestone payments related to Xen45, a minimally invasive implantable shunt to reduce IOP in patients with glaucoma.